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NMDA receptor antagonism by phencyclidine reduces NWASP and WAVE1 
protein expression and reduces levels of myelination markers in the prefrontal 
cortex of rats 
Abstract 
N-methyl-D-aspartate (NMDA) receptor antagonism by perinatal phencyclidine (PCP) treatment leads to 
neuronal damage and causes long-term behavioural alterations in rodents. It is routinely used to model 
pathological processes in the brain that may be present in schizophrenia, such as alterations to dendritic 
development, and disruptions to myelin processes. Both of these processes occur during brain 
development and are highly implicated in the schizophrenia pathophysiology. Changes to the 
polymerization and reorganization of the actin cytoskeleton can have significant effects on the 
morphology and dynamics of the dendrites within the brain. Actin regulation is primarily regulated by 
neural Wiskott-Aldrich syndrome protein (NWASP), and WASP-family verprolin homology protein-1 
(WAVE1). Here we have examined the role of actin related, cytoskeletal proteins NWASP and WAVE1 in a 
neurodevelopmental model of schizophrenia using PCP to determine if these signaling pathways are 
altered in the prefrontal cortex and hippocampus throughout different stages of neurodevelopment. Male 
Sprague Dawley rats were injected subcutaneously with PCP (10 mg/kg) or saline at postnatal days (PN) 
7, 9 and 11. Rats (n=6/group) were sacrificed at PN 12, 5 weeks or 14 weeks. Relative expression levels of 
protein expression were examined in the prefrontal cortex and hippocampus of the treated rats. NWASP, 
WAVE1 and MBP were decreased (0.001≤p≤0.032) in the prefrontal cortex of PCP treated rats at PN12. 
At 5 weeks of age, NWASP was reduced in the prefrontal cortex (p=0.037) and WAVE1 was reduced in the 
hippocampus (p=0.006). At 14 weeks, there were no significant changes in any of the tested proteins 
(p>0.05). This is the first report of an alteration in NWASP and WAVE1 proteins in the rat brain, directly 
following NMDA receptor antagonism by PCP treatment in early development. These findings suggest 
that alterations in these important scaffolding related proteins may contribute to the development of 
deficits in myelination and cognitive performance in the brain. 
Disciplines 
Medicine and Health Sciences 
Publication Details 
Andrews, J. L., Newell, K. A., Matosin, N., Huang, X. & Fernandez-Enright, F. (2015). NMDA receptor 
antagonism by phencyclidine reduces NWASP and WAVE1 protein expression and reduces levels of 
myelination markers in the prefrontal cortex of rats. Journal of Pharmaceutics & Pharmacology, 3 (1), 1-8. 
This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/515 
Citation: Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. NMDA Receptor Antagonism by Phencyclidine Reduces NWASP and 
WAVE1 Protein Expression and Reduces Levels of Myelination Markers in the Prefrontal Cortex of Rats. J Pharmaceu Pharmacol. 2015;3(1): 8.
J Pharmaceu Pharmacol
February 2015 Vol.:3, Issue:1
© All rights are reserved by Fernandez-Enright et al.
NMDA Receptor Antagonism 
by Phencyclidine Reduces 
NWASP and WAVE1 Protein 
Expression and Reduces Levels 
of  Myelination Markers in the 
Prefrontal Cortex of  Rats
Keywords: Neural Wiskott-Aldrich syndrome protein; WASP-family verprolin 
homology protein-1; Neurodevelopmental animal model; Schizophrenia; Myelin 
markers
Abstract
N-methyl-D-aspartate (NMDA) receptor antagonism by perinatal 
phencyclidine (PCP) treatment leads to neuronal damage and 
causes long-term behavioural alterations in rodents. It is routinely used 
to model pathological processes in the brain that may be present 
in schizophrenia, such as alterations to dendritic development, and 
disruptions to myelin processes. Both of these processes occur during 
brain development and are highly implicated in the schizophrenia 
pathophysiology. Changes to the polymerization and reorganization of 
the actin cytoskeleton can have significant effects on the morphology 
and dynamics of the dendrites within the brain. Actin regulation 
is primarily regulated by neural Wiskott-Aldrich syndrome protein 
(NWASP), and WASP-family verprolin homology protein-1 (WAVE1). 
Here we have examined the role of actin related, cytoskeletal proteins 
NWASP and WAVE1 in a neurodevelopmental model of schizophrenia 
using PCP to determine if these signaling pathways are altered in 
the prefrontal cortex and hippocampus throughout different stages 
of neurodevelopment. Male Sprague Dawley rats were injected 
subcutaneously with PCP (10 mg/kg) or saline at postnatal days (PN) 
7, 9 and 11. Rats (n=6/group) were sacrificed at PN 12, 5 weeks or 14 
weeks. Relative expression levels of protein expression were examined 
in the prefrontal cortex and hippocampus of the treated rats. NWASP, 
WAVE1 and MBP were decreased (0.001≤p≤0.032) in the prefrontal 
cortex of PCP treated rats at PN12. At 5 weeks of age, NWASP was 
reduced in the prefrontal cortex (p=0.037) and WAVE1 was reduced 
in the hippocampus (p=0.006). At 14 weeks, there were no significant 
changes in any of the tested proteins (p>0.05). This is the first report of 
an alteration in NWASP and WAVE1 proteins in the rat brain, directly 
following NMDA receptor antagonism by PCP treatment in early 
development. These findings suggest that alterations in these important 
scaffolding related proteins may contribute to the development of 
deficits in myelination and cognitive performance in the brain.
Introduction
Glutamate is the primary excitatory neurotransmitter in the brain 
and through its actions predominantly on NMDA receptors, plays a 
key role in neurodevelopmental processes such as neuronal migration, 
synaptogenesis and synaptic plasticity in both cortical and sub cortical 
regions [1]. Phencyclidine or 1-(1-phenylcyclohexyl) piperidine 
(also known as PCP) is a potent non-competitive NMDA receptor 
antagonist [2-4]. To a lesser extent, PCP also has a lower binding 
affinity for several other targets including dopaminergic D2, nicotinic 
and muscarinic cholinergic receptors, as well as μ, κ and σ classes of 
opiate receptors [5-8]. In healthy human subjects, administration 
of PCP induces hallucinations and delusions which are common 
symptoms of schizophrenia; furthermore the administration of PCP 
to schizophrenia patients exacerbates their positive symptoms [9], 
thus a number of pharmacological models of schizophrenia have been 
developed using the administration of PCP to rodents (for review see 
[9]). Since the effects of PCP treatment in rodents are translatable 
to humans and other higher order primates, the administration 
of PCP is now one of the best known pharmacological models of 
schizophrenia [10,11]. Administering perinatal PCP to postnatal 
rodents has both the construct validity and face validity to test and 
address the proposed neurodevelopmental origins of schizophrenia. 
The administration of PCP at postnatal day (PN) 7, 9 and 11, which 
broadly corresponds to the second trimester of pregnancy in humans 
[12], has consistently been shown to induce hyperlocomotion, reduce 
prepulse inhibition and impair social interactions in rodents in 
adulthood [13-15], as previously published by our research group. All 
these behaviors illustrate symptoms encountered in schizophrenia 
pathology [9]. Due to its effects on a multitude of important 
receptor targets known to be involved in the pathophysiology of 
schizophrenia, and the schizophrenia-like behaviors, and symptoms 
it induces in rodents and humans respectively, PCP administration in 
rodents is now one of the most commonly used models for studying 
the development of schizophrenia [3,16,17]. In the postnatal period, 
from about PN7 to 14, neurons are highly sensitive to the toxic 
effects of NMDA receptor antagonists [18]; however neurons are 
not the only brain cells that are affected by disruptions to NMDA 
receptor antagonists. Oligodendrocytes are also very sensitive to PCP 
toxicity during development [19], and since they play a significant 
role in axonal connectivity and conduction, disruption to these 
processes during the early stages of brain development could impact 
significantly on normal brain development in its later stages.
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In addition to oligodendrocytes playing a significant role in nerve 
conductivity and communication, postsynaptic dendritic spines 
are also largely responsible for information processing and storage 
in neurons, as well as synaptic plasticity [20], all of which critically 
underlie learning and memory processes. Within the dendrites, it is 
the configuration of the actin cytoskeleton that is largely responsible 
for the regulation of synaptic spine formation and morphology; 
thus changes to the polymerization and reorganization of the actin 
cytoskeleton can have a significant impact on the morphology 
and dynamics of dendritic spines, which could lead to cognitive 
dysfunction [21].
Polymerization, reorganization and branching of the actin 
cytoskeleton are primarily regulated by the actin-related proteins 
(Arp2/3) complex. The binding of the Arp2/3 complex to the side 
of an existing actin filament elicits the polymerization of actin, 
resulting in filament branching [22]. The Arp2/3 complex is primarily 
regulated by neural Wiskott-Aldrich syndrome protein (NWASP), 
and WASP-family verprolin homology protein-1 (WAVE1) 
[23]. Loss of hippocampal NWASP and Arp3 has been shown to 
significantly reduce both the number of dendritic spines and the 
number of excitatory synapses [24]. Furthermore, genetic knockout 
of WAVE1 leads to hippocampal and cortical dysfunction, through 
a reduction in spine density and alterations in synaptic transmission 
[25]. WAVE1 knockout mice demonstrate learning and memory 
deficits, and display reduced sensorimotor function [26].
Since neuronal changes in NWASP and WAVE1 expression 
have been shown to induce alterations in dendritic spine growth 
and synaptic transmission [24,25,27], which both underlie learning 
and memory processes; we examined the levels of expression of 
these proteins throughout development in the prefrontal cortex and 
hippocampus of rats following perinatal administration of the potent 
NMDA receptor antagonist PCP. Furthermore, we also examined 
levels of myelination related proteins myelin basic protein (MBP) 
and myelin oligodendrocyte glycoprotein (MOG), since NWASP and 
WAVE1 are also critically involved in oligodendrocyte differentiation 
and myelination [28,29] which are also implicated in cognition.
Materials and Methods
Animals
Timed pregnant Sprague Dawley rats were obtained at gestation 
day 14 from the Animal Resource Centre (Perth, WA, Australia). 
They were housed in environmentally controlled conditions at 22 °C 
in a 12:12 hour light dark cycle with free access to food and water. The 
day of birth was considered PN0. Pups were sexed on PN7 and were 
randomly assigned to PCP or saline groups. The female pups were 
kept in the litters, however only male rats were used in this study. 
Pups were weaned at PN24-28, and were housed in pairs according to 
treatment. This study was approved by the Animal Ethics Committee 
at the University of Wollongong (AE13/01), and was conducted 
according to the guidelines of the Australian code of Practice for the 
Care and Use of Animals for Scientific Purposes, conforming to the 
International Guiding Principles for Biomedical Research Involving 
Animals. All efforts were made to minimize numbers of animals used 
and their suffering.
Perinatal PCP treatment
Male Sprague Dawley rat pups were given a subcutaneous 
injection on PN7, 9 and 11; of PCP (10 mg/kg/day; Sigma, Castle Hill, 
NSW, Australia) or saline (0.9% NaCl at a volume of 1 ml/kg), as our 
group and others have previously shown that this treatment regime 
produces PCP induced alterations in sensorimotor gating, locomotor 
activity and working memory in rats [13,14,30,31]. Additionally, the 
acute effects of PCP administration were validated by observing an 
immediate increase in locomotor activity in the PCP treated pups 
compared to saline treated pups. Six rats from each group (PCP and 
control) were sacrificed at three different time points, PN12 days, 5 
weeks or 14 weeks of age as described previously [18,32]. These time-
points represent perinatal, adolescent and adult developmental stages 
respectively, and were chosen because they are relevant and distinct 
brain developmental periods [33].
Rat brain tissue preparation
Rats were sacrificed by carbon dioxide asphyxiation and 
decapitation at PN12, 5 weeks and 14 weeks. Brains were rapidly 
removed and the prefrontal cortex and hippocampus was regionally 
dissected on ice with the aid of a standard rat brain atlas [34]. Samples 
were snap frozen in liquid nitrogen and then stored at -80 °C. Tissue 
was homogenized gently in a homogenizing buffer (50 mM Tris pH 
7.5, 50 % glycerol), containing a protease inhibitor cocktail (Sigma). 
Protein concentrations were determined by a spectrophotometer. All 
samples were diluted to a concentration of 2 μg/μL and stored at -80 
°C until required for immunoblotting, as previously detailed [35].
Immunoblotting
Relative levels of all proteins were determined by immunoblot 
analysis as previously described [35]. In short, proteins were resolved 
by SDS-PAGE with a total of 10 µg protein loaded into each well of 
the gel. Separated proteins were then transferred to polyvinylidene 
fluoride membranes (Bio-Rad). Membranes were probed with anti-
NWASP (1:1000; ab23394 Abcam), anti-WAVE1 (1:2500; ab50356 
Abcam), anti-MBP (1:1000; ab53294 Abcam), and anti-MOG 
(1:10000; MAB5680 Millipore) primary polyclonal or monoclonal 
antibodies. Visualization and quantification of immunoblot bands 
was performed using the Gel Logic 2200 Pro (Carestream Molecular 
Imaging; Rochester, NY, USA). Samples were loaded in a randomized 
order with even numbers of PCP and control samples per time point 
per gel to minimize the effects of gel-to-gel variability on the results. 
A pooled sample combining aliquots from all 36 rats, was used as a 
positive control and was loaded onto each gel within the experiment 
to account for any gel-to-gel variability. Samples from each gel 
were then normalized to their respective pooled sample, and all 
immunoblot bands were normalized to a β-actin (1:5000; MAB1501 
Millipore) same lane loading control. Mean β-actin expression 
levels did not differ between PCP and control groups (p>0.05). All 
experiments and quantifications were performed blind to treatment 
and age group.
Statistics
Statistical analyses were performed using SPSS (version 20.0, 
SPSS Inc. Chicago, USA). Protein analyses were performed on 5-6 
biological replicates per treatment per time-point, with experiments 
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performed in 2-3 technical replicates. As all data were normally 
distributed (K-S p>0.10), parametric testing was implemented. 
Differences between treatment and control groups were analyzed 
at individual time-points using unpaired two-tailed t-tests. The 
significance for all statistical tests was set to p<0.05.
Results
Prefrontal cortex
PN12: Relative levels of NWASP expression were found to be 
significantly decreased by 23.5% in the prefrontal cortex of perinatal 
PCP treated rats at PN12 (t1,7=2.665; p=0.032; Figure 1). Similarly, 
WAVE1 expression levels were also found to be significantly decreased 
by 17.5% in PCP treated rats compared to control rats at PN12 
(t1,7=6.117; p<0.001; Figure 1). Furthermore, there was a significant 
17.5% decrease in the protein expression of the myelination marker 
MBP in rats treated with PCP compared to control rats at PN12 
(t1,7=3.266; p=0.013; Figure 1); however there were no significant 
alterations in expression levels of the MOG marker of myelination (t-
1,10=1.345; p=0.208) in the PN12 PCP treated rats compared to control 
rats (Figure 1).
5 weeks: Interestingly, NWASP was the only protein to show 
significant alterations in expression levels in the prefrontal cortex 
of the adolescent 5 week old rats; and it was only a minor change 
with an 8% decrease in NWASP expression in the PCP treated rats at 
adolescence (t1,10=2.405; p=0.037; Figure 1). There were no significant 
alterations in the expression levels of WAVE 1(t1,10=0.4676; p=0.650), 
or in either of the myelination markers MBP (t1,8=0.5707; p=0.5838) 
Figure 1: Levels of protein expression in the prefrontal cortex of phencyclidine (PCP) treated rats (black bars) compared to controls (white bars).* p<0.05 and *** 
p<0.001.
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or MOG (t1,10=0.6339; p=0.540) in the 5 week PCP treated rats 
compared to control rats (Figure 1).
14 weeks: Perinatal PCP treatment resulted in no significant 
alterations in cortical levels of NWASP protein at 14 weeks during 
adulthood (t1,10=0.5414; p=0.601; Figure 1). Additionally there 
were no significant differences in WAVE1 expression in the PCP 
treated rats compared to controls (t1,10=0.1405; p=0.891; Figure 1). 
Furthermore, levels of expression of both of the tested myelination 
markers MBP (t1,9=0.1987; p=0.847) and MOG (t1,9=0.2912; p=0.777) 
were unaltered in the 14 week perinatal PCP treated rats compared to 
controls (Figure 1).
Hippocampus
PN12: There was a very large 42% decrease in hippocampal 
WAVE1 protein expression in juvenile PCP treated rats compared to 
control rats (t1,10=3.659; p=0.004; Figure 2). In contrast, relative protein 
expression levels of NWASP (t1,10=1.456; p=0.176), and myelination 
markers MBP (t1,8=1.509; p=0.169) and MOG (t1,10=0.0447; p=0.965) 
were not significantly altered in the hippocampus of juvenile PCP 
treated rats (Figure 2).
5 weeks: Similarly, during adolescence, WAVE1 was the only 
protein to be significantly altered, with a decrease of 16% in PCP 
treated rats compared to controls (t1,10=3.428; p=0.006; Figure 2); 
whereas levels of NWASP (t1,10=0.0444; p=0.965), MBP (t1,9=1.067; 
p=0.314) and MOG (t1,10=0.1822; p=0.859) remained unaltered in the 
hippocampus of the adolescent treated rats (Figure 2).
14 weeks: Perinatal PCP treatment resulted in no significant 
alterations in hippocampal levels of NWASP protein during 
adulthood (t1,10=1.385; p=0.1962; Figure 2). Additionally there were 
Figure 2: Levels of protein expression in the hippocampus of phencyclidine (PCP) treated rats (black bars) compared to controls (white bars). ** p<0.01.
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no significant differences in adult levels of hippocampal WAVE1 
expression in the PCP treated rats compared to controls (t1,10=0.8784; 
p=0.401; Figure 2). Furthermore, levels of expression of both of the 
tested myelination markers MBP (t1,7=0.2870; p=0.7824) and MOG 
(t1,9=0.7322; p=0.4827) were unaltered in the 14 week perinatal PCP 
treated rats compared to controls (Figure 2).
Discussion
This is the first study to examine the developmental expression 
profile of the scaffolding proteins NWASP and WAVE1, in addition 
to myelin related proteins MBP and MOG in a neurodevelopmental 
PCP model of schizophrenia. This study offers insight into the role of 
these proteins following administration of a potent NMDA receptor 
antagonist during a critical neurodevelopmental period, which is 
also pertinent to the development of schizophrenia. In the present 
study, cortical levels of protein expression of NWASP, WAVE1 and 
MBP were significantly reduced in the juvenile PCP treated rats, and 
cortical levels of NWASP were slightly reduced in the adolescent PCP 
treated rats. In the hippocampus, WAVE1 was the only protein to 
have its expression levels altered, with a significant decrease observed 
in both PN12 and 5 week old PCP treated rats compared to their 
controls. Considering the current literature and the role that these 
scaffolding and myelin related proteins play in synaptic plasticity 
and myelin related processes, our results suggest that not only are 
NWASP and WAVE1 sensitive to the effects of NMDA receptor 
antagonism by PCP, but that they may contribute to the development 
of myelination deficits in the brain.
NMDA receptor antagonism by PCP acutely reduces 
expression of NWASP, WAVE1 and MBP proteins in the 
prefrontal cortex of juvenile rats
Impaired glutamate signaling results in significant alterations 
in synapse number and synaptic communication, and has been 
correlated with neuronal, cognitive and behavioral dysfunction in 
a wide range of neuropsychiatric disorders including schizophrenia 
[36]. Similarly, PCP administration in rats has been shown to 
significantly reduce the number of dendritic spine synapses in the 
prefrontal cortex, for up to 4 weeks following the cessation of PCP 
treatment [37,38], and induce significant cognitive impairment 
in both monkeys [39] and rats [40-43]. NWASP and WAVE1 are 
important regulatory proteins involved in maintaining the actin 
cytoskeleton [22] and are critical for the development of dendritic 
spines and synapses [24,25].We have shown NWASP and WAVE1 
protein expression to be significantly reduced in the prefrontal cortex 
of juvenile PCP treated rats compared to controls. Since neuronal 
changes in NWASP and WAVE1 expression have been shown to result 
in alterations in dendritic spine growth and synaptic transmission 
[24,25,27], it was not surprising to find significant reductions of 
both of these proteins in the prefrontal cortex of PCP treated rats. 
Significant deficits in NWASP and WAVE1 protein expression have 
previously been observed in NMDA receptor knock-down mice, with 
the reduced levels of the NMDA receptor having a more profound 
effect of on WAVE1 expression [44].
The integrity of myelin is crucial to the functionality of 
neurocircuitry, and disruption to myelin during development, or 
even after its formation can have severe neurological consequences 
[45]. Oligodendrocytes are known to express several regulatory actin-
binding proteins including NWASP [28], and NWASP knockout 
PN10 neuronal cultures have been shown to have severely reduced 
levels of myelin related gene expression, whereby only trace amounts 
of MBP were detectable in the NWASP mutant cells compared to 
controls [46]. Moreover, WAVE1 knockout mice show defective 
morphogenesis of oligodendrocytes and regional hypo-myelination 
[29]. In addition, both NWASP and WAVE1 protein expression 
levels are increased at PN15, the time of onset of MBP expression 
in rat brain lysates [47]. To date only two studies have shown 
myelination deficits in rodents following PCP administration. One 
study administered PCP to the rats in utero [48], and the other to 
postnatal rat pups [49]. Both studies reported significant deficits in 
levels of myelination, as measured by MBP expression, in the cortex 
of rats exposed to PCP compared to controls [48,49]. In light of the 
current literature, we hypothesize that the deficits in MBP levels that 
we have observed in the prefrontal cortex of juvenile PCP treated rats 
may be caused by the significant downregulation of NWASP and 
WAVE1 proteins in the treated rats.
Myelination processes in the hippocampus occur during the 
embryonic period which is a pivotal period for the development 
of schizophrenia [50], while myelination of the neurons within the 
dorsolateral prefrontal cortex occurs in late adolescence, which 
correlates with the age of onset of schizophrenia [51]. Despite MBP 
and MOG levels being unaltered in the hippocampus of PCP treated 
rats compared to control rats in all of the tested age groups, MBP 
levels as a marker of mature oligodendrocytes and myelination 
were significantly greater in the hippocampus than in the prefrontal 
cortex of the juvenile control rats (p=0.002) whereas they were 
not significantly different in PCP treated rats (p=0.141) (Figure 3). 
Furthermore although not reaching statistical significance, MBP 
levels were elevated in the prefrontal cortex of PCP treated compared 
to control rats at adolescence. These juvenile and adolescent MBP 
levels seen in our study are in accordance with what would be expected 
to occur in normal brain development, with the hippocampus being 
more highly myelinated during early development, and the prefrontal 
cortex being slow to begin with, but taking over at adolescence [50].
It is interesting that we reported differential expression patterns 
of myelin related protein expression across the prefrontal cortex 
and hippocampus following perinatal PCP treatment in this study; 
however it is not uncommon to observe variations in expression 
patterns within different regions of the brain due to the regional 
differences in heterogeneity in cyto- and chemo-architecture. We 
suspect that the perinatal PCP treatment may have affected the 
developmental trajectories of these myelin related proteins to varying 
degrees early on in development.
Hippocampal levels of WAVE1 but not NWASP or myelin 
related proteins MBP and MOG are altered by perinatal 
PCP administration
Hippocampal expression levels of WAVE1 were found to be 
significantly decreased in PCP treated rats compared to control rats 
at both juvenile and adolescent time-points, whereas hippocampal 
levels of NWASP were not found to be significantly altered by PCP 
treatment. In support of this, expression levels of WAVE1 have been 
shown to be more susceptible to the effects of NMDA receptor knock-
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down than those of NWASP [44], and WAVE1 expression is not 
detectable in the hippocampus of WAVE1 knockout mice [26].
WAVE1 expression has been shown to be specific to the brain 
in mice, with the highest expression levels being detectable in the 
striatum, cortex and hippocampus [26]. Genetic knockout of WAVE1 
results in significant reductions in hippocampal and cortical dendritic 
spine densities, and alterations in synaptic plasticity [25] along with 
deficits in learning and memory [26]. In line with the literature, 
we hypothesize that the significant reduction in WAVE1 protein 
expression observed in our PCP treated rats, may be at least partly 
responsible for the synaptic and behavioural deficits observed in 
schizophrenia animal models involving NMDA receptor antagonism. 
In further support of our hypothesis, both NMDA receptor knock-
down mice and PCP treated rats, in addition to WAVE1 knockout 
mice show similar alterations in their behavior and synaptic 
morphology [25,26,37,44,52].
Even though the change in NWASP was very minimal across 
development, both NWASP and WAVE1 proteins were increased 
during adolescence (Figure 2). Due to the extensive synaptic changes 
that occur during adolescence (reductions in dendritic arborization, 
and pruning of synapses) [53], it was not surprising to observe higher 
levels of these important regulators of the actin cytoskeleton at this 
critical period of development in the control rats.
Cognitive deficits observed in patients with schizophrenia are 
particularly attributable to prefrontal cortex and hippocampal 
dysfunction, and since a large number of studies have consistently 
found that the largest changes in the expression of oligodendrocytes 
and myelin-related genes in schizophrenia are in the prefrontal 
cortex, cingulate cortex, hippocampus and superior temporal gyrus 
[54-59], it seems plausible to suggest that the cognitive dysfunction 
seen in schizophrenia is related to the alterations in myelin-related 
genes in these regions. As briefly mentioned above, while we did 
not observe hippocampal levels of myelin related proteins to be 
significantly altered in PCP treated rats compared to controls, we did 
notice that hippocampal levels of these proteins were not significantly 
different from those observed in the prefrontal cortex of PCP treated 
rats, whereas in control rats these levels were significantly different 
at PN12 (Figure 3). We hypothesize that the lack of a statistically 
significant difference in the hippocampus compared to the prefrontal 
cortex levels of myelin related proteins in PCP treated rats, may be 
playing a role in some of the PCP induced cognitive deficits that are 
observed in rodent models of schizophrenia, long-term abusers of PCP 
[38], and in schizophrenia patients [45]. In support of this, injections 
of potent demyelination agents into the ventral hippocampus of 10 
day old rat pups has been shown to induce a variety of schizophrenia 
related endophenotypes, including deficits in prepulse inhibition, 
hyper locomotion and inducing anxiety related behaviors, suggesting 
that demyelination plays an important role in the development and 
severity of schizophrenia [60].
Summary and Conclusion
Here we provide the first report of alterations in the actin related 
cytoskeletal proteins NWASP and WAVE1, in the prefrontal cortex 
and hippocampus of rats from a neurodevelopmental PCP model of 
schizophrenia. We have shown an altered developmental trajectory of 
these signaling proteins following PCP administration, in particular 
at the perinatal stage of life. The results of this study in concert with 
the current literature, suggest that NWASP and especially WAVE1 
are sensitive to the effects of NMDA receptor antagonism by PCP 
administration, and that alterations in these scaffolding related 
proteins may contribute to the development of myelination deficits 
in the brain, and more broadly, deficits in cognitive performance. 
Further studies will be required to fully elucidate the molecular 
mechanisms involved.
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